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The Opioid Crisis
With over 52,000 deaths a year, drug-related overdoses 
are the leading cause of accidental death in adults in the 
United States.1 In 2016 there were 1,990 confirmed deaths 
from opioid overdoses in Massachusetts, which is a 19% 
increase from 2015.2 The opioid epidemic has resulted in 
national efforts to develop and implement scientifically-
based and practical solutions to help individuals at highest 
risk for substance use and overdose, specifically those 
involved with the criminal justice system. 
Drug Treatment Courts & Dropouts
Research indicates that 50 to 70 percent of individuals 
involved with the criminal justice system meet criteria 
for substance use disorders and are at increased risk for 
overdose.3 In Massachusetts, former inmates who were 
recently released from prison were 56 times more likely to 
die of drug overdoses than community members who had 
not been recently incarcerated.4 Drug Treatment Courts 
(DTCs), specialty courts that mandate probationers to 
participate in substance use treatment, seek to aid this 
high risk population. DTCs are effective in reducing drug 
and alcohol use,5-8 but have early dropout (or failure to 
complete the program) rates as high as 75%.6 Predictably, 
individuals who do not complete the Drug Treatment 
Program are more likely to continue using substances, 
have more frequent relapses, and continue to engage in 
high risk behaviors.6 Accordingly, identifying individuals 
most likely to dropout and helping them to remain in 
treatment programs is critical to decreasing substance use 
in this population. 
Role of Quality of Life in DTC Dropout
Past research has focused on DTC dropouts as a function 
of participant characteristics (e.g., age, criminal history) 
or treatment program features (e.g., frequency of DTC 
hearings).8 Our study, The Impact of Health-Related Quality 
of Life on Retention in Drug Treatment Courts, proposes 
to shift the focus to health-related Quality of Life (QOL) 
and its impact on dropout. QOL examines self-perceived 
physical and mental health and its effect on daily functioning9 
and has been shown to predict retention in various treatment 
models.10-12 Federal agencies13 and researchers identify QOL as 
an important outcome of substance use treatment. Yet, QOL 
has never been examined in DTC participants. 
We hypothesize that individuals who have worse QOL also 
have greater daily physical and emotional health difficulties, 
and thereby are less able to participate in DTCs, resulting in 
high rates of dropout. If we can use QOL to better identify 
individuals who are most likely to dropout of treatment, we 
can then develop interventions to improve individuals’ overall 
functioning and QOL. 
Aims
1. To evaluate the applicability and feasibility of QOL 
measures in Drug Treatment Courts populations.
2. To assess whether Drug Treatment Courts produce 
improvements in QOL and other psychosocial factors 
such as social support and self-efficacy about drug and 
alcohol abstinence.
3. To examine whether QOL can predict attrition from Drug 
Treatment Courts. 
To this end, seven DTC participants will be asked to participate 
in a brief interview and complete self-report questionnaires at 3 
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time points: 1) within one month of enrollment into a DTC, 2) at 6 
months, and 3) at 12 months. Data will be collected to learn about 
what impacts the participant’s QOL scores and other psychosocial 
variables, as well as retention in DTCs. 
Our ultimate goal is to improve retention in DTCs and substance use 
treatment. Findings from this study will produce pilot data to aid in 
the development of an intervention to improve QOL and presumably 
retention in DTCs. 
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